Advertisement

Topics

PubMed Journals Articles About "Thermography In Assessing Treatment Response To Golimumab In Psoriatic Arthritis" RSS

12:17 EST 12th December 2018 | BioPortfolio

Thermography In Assessing Treatment Response To Golimumab In Psoriatic Arthritis PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Thermography In Assessing Treatment Response To Golimumab In Psoriatic Arthritis articles that have been published worldwide.

More Information about "Thermography In Assessing Treatment Response To Golimumab In Psoriatic Arthritis" on BioPortfolio

We have published hundreds of Thermography In Assessing Treatment Response To Golimumab In Psoriatic Arthritis news stories on BioPortfolio along with dozens of Thermography In Assessing Treatment Response To Golimumab In Psoriatic Arthritis Clinical Trials and PubMed Articles about Thermography In Assessing Treatment Response To Golimumab In Psoriatic Arthritis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Thermography In Assessing Treatment Response To Golimumab In Psoriatic Arthritis Companies in our database. You can also find out about relevant Thermography In Assessing Treatment Response To Golimumab In Psoriatic Arthritis Drugs and Medications on this site too.

Showing "Thermography Assessing Treatment Response Golimumab Psoriatic Arthritis" PubMed Articles 1–25 of 41,000+

Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.

A network meta-analysis using randomized controlled trial data compared psoriatic arthritis (PsA) outcomes (American College of Rheumatology [ACR], Psoriasis Area Severity Index [PASI] and Psoriatic Arthritis Response Criteria [PsARC] response rates) at 12-16 weeks for secukinumab, adalimumab, apremilast, certolizumab, etanercept, golimumab, infliximab and ustekinumab.


Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany.

The TNF inhibitor golimumab (GLM) is a treatment option in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). The GO-NICE study assessed patient-reported outcomes (PRO) in patients newly treated with monthly GLM 50 mg subcutaneously (SC) under real-life conditions in Germany. A prospective non-interventional study with 24-month observation per patient was conducted at 158 sites. Available for analysis were 1,458 patients, 474 with rheumatoid arthritis (RA: ...

Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis.

Psoriasis and psoriatic arthritis cause significant physical and psychological burdens for afflicted individuals. An accelerated TNF-α/IL-23/IL-17 axis is their major pathomechanism; therefore, anti-TNF-α/IL-23/IL-17 biologics are very effective for the treatment of skin and joint lesions in psoriasis and psoriatic arthritis. Given that the IL-17 signature is more upregulated in the skin than in synovium in psoriatic arthritis, anti-IL-23/IL-17 agents seem to be superior to anti-TNF-α remedies in the tre...


Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP).

There are scarce data in Scandinavia about treatment satisfaction among patients with psoriasis (PsO) and/or psoriatic arthritis (PsA). The number of patients receiving systemic treatment is unknown.

Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

Golimumab immunogenicity was extensively studied during clinical development. As anti-drug antibody (ADA) detection with the standard bridging EIA (original-EIA) can yield false-negative results or underestimate ADA incidence and titres due to drug interference, a more sensitive assay was needed to determine clinical impact.

Identification of a Single Nucleotide Polymorphism in NFKBIA with Different Effects on Psoriatic Arthritis and Cutaneous Psoriasis in China.

Genome-wide association studies have recently identified a number of non-major histocompatibility complex regions associated with psoriatic arthritis. However, data on Chinese patients with psoriatic arthritis and the differences between psoriatic arthritis and cutaneous psoriasis are limited. This study genotyped 12 single nucleotide polymorphisms in 379 patients with psoriatic arthritis, 376 with cutaneous psoriasis, and 760 healthy controls using Sequenom's Mass ARRAY system. The aim of the study was to ...

Treatment of psoriatic arthritis with secukinumab: a case series.

Psoriatic arthritis (PsA) is a chronic inflammatory disorder affecting up to 30% of psoriatic patients, worsening patients' quality of life. Secukinumab, a fully humanized monoclonal antibody that selectively inhibits interleukin (IL) 17A, has been recently approved for the treatment of PsA in adults, alone or in association with methotrexate (MTX). In the secukinumab registration studies, the primary endpoint was evaluated at 24 weeks; whether there is an early response in patients with psoriatic arthritis...

The GO-DACT protocol: a multicentre, randomized, double-blind, parallel-group study to compare the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy.

The GO-DACT is an investigator-initiated, national, multicentric randomized placebo-controlled double-blinded trial, that assesses dactylitis as primary endpoint. Psoriatic arthritis patients naïve to methotrexate and biologic disease modifying anti-rheumatic drugs, with at least one active dactylitis, were assigned to golimumab in combination with methotrexate or placebo in combination with methotrexate, for 24 weeks. Both clinical (dactylitis severity score and the Leeds dactylitis index) and imaging (hi...

Ustekinumab for the treatment of psoriasis and psoriatic arthritis: A drug evaluation and literature review.

Psoriasis is an autoimmune, inflammatory disorder characterized by proliferation of keratinocytes, and it may be associated with a systemic inflammatory articular disorder, psoriatic arthritis. The presentations of psoriasis and psoriatic arthritis are heterogeneous, and our understanding of the underlying pathogenesis has led to a better understanding of the vital role of the IL-23/Th17 immune axis. Areas covered: Ustekinumab is a monoclonal antibody against IL-12 and IL-23, and this review will focus on i...

Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: A prospective cohort study.

To study the prognostic value of widespread pain and of musculoskeletal ultrasound (US) examination for subsequent treatment outcomes in patients with psoriatic arthritis (PsA).

Assessing Disease Activity in Psoriatic Arthritis: A Literature Review.

Psoriatic arthritis (PsA) is a multifaceted disease, with a high impact on patients' psychological and physical well-being. There is increasing recognition that assessment of both clinical aspects of disease and patient identified concerns, such as fatigue, work disability, and treatment satisfaction need to be addressed. Only then can we fully understand disease burden and make well-informed treatment decisions aimed at improving patients' lives. In recent years, there has been much progress in the develop...

Safety of Ixekizumab in Patients with Psoriatic Arthritis: Results from a Pooled Analysis of Three Clinical Trials.

To evaluate ixekizumab safety in adults with psoriatic arthritis (PsA).

The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients.

For patients with rheumatoid arthritis (RA) who do not respond or lose response to anti-tumor necrosis factor (TNF) biologics, switching to a different anti-TNF can be an effective means to manage symptoms and disease progression. This study examined the utilization and effectiveness of intravenous golimumab within a real-world population of patients with RA switching directly from infliximab, a potent anti-TNF.

Back pain in psoriatic arthritis: defining prevalence, characteristics and performance of inflammatory back pain criteria in psoriatic arthritis.

We aimed to determine the agreement between rheumatologist-judged inflammatory back pain (IBP) and criteria defining IBP in patients with psoriatic arthritis (PsA) and predictive value of IBP in identifying axial involvement in PsA.

Management of Psoriatic Arthritis: Turkish League Against Rheumatism (TLAR) Expert Opinions.

This study aims to establish the first national treatment recommendations by the Turkish League Against Rheumatism (TLAR) for psoriatic arthritis (PsA) based on the current evidence.

Incidence and Predictive Factors for Orthopedic Surgery in Patients with Psoriatic Arthritis.

To investigate the incidence of orthopedic procedures in patients with psoriatic arthritis (PsA), and how patient characteristics, time of diagnosis, and treatment affect the need for surgery.

Golimumab tapering strategy based on drug serum levels in SPA-PAZ Spondyloarthritis cohort.

Golimumab (GLM) is a tumor necrosis factor inhibitor (TNFi) used as Spondyloarthritis (SpA) treatment . There is increasing evidence of the feasibility of using TNFi levels as a guide for clinicians to an optimized strategy . Up to now, a few studies have investigated the predictive value of GLM-levels in the clinical response of several inflammatory diseases , but none concerning GLM reduction therapy in SpA based on drug-levels measurement is available. This article is protected by copyright. All rights r...

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.

Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). This post hoc analysis assessed the efficacy of tofacitinib using pooled data from two phase 3 studies of patients with active PsA.

Novel Therapeutics in Psoriatic Arthritis. What Is in the Pipeline?

To highlight the recently approved therapeutic agents in psoriatic arthritis (PsA), drugs in the pipeline, as well as to discuss efficacy with regard to different clinical domains of PsA.

Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-label Trial of Patients With Ulcerative Colitis.

Golimumab, a tumor necrosis factor (TNF) antagonist, is an effective treatment for patients with moderate-to-severe ulcerative colitis (UC). However, more than 50% of initial responders lose their response to the drug within the first year of therapy. A gene expression signature identified in colon biopsies collected before treatment was associated with response to infliximab, and was subsequently refined to associate with mucosal healing in response to golimumab. We performed a phase 2a open label study of...

Tofacitinib for the treatment of psoriasis and psoriatic arthritis.

Psoriasis and psoriatic arthritis (PsA) are inflammatory immune mediated conditions which can cause considerable disability and reduced quality of life. Management can be complex as clinical heterogeneity may lead to different treatment pathways. Tofacitinib is a novel, oral janus kinase (JAK) inhibitor with proven efficacy in rheumatoid arthritis. Areas covered: This review analyses recent studies of tofacitinib in psoriatic disease treatment. The relevant literature was identified using clinicaltrials.gov...

The Role of IL-17 in the Human Immune System and Its Blockage as a Treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis.

Interleukin 17 (IL-17) functions as a bridge between the innate and adaptive immunity. In addition to being a crucial defense mechanism against extracellular pathogens, it plays a significant role in inflammation, therefore considered a decisive factor in inflammatory conditions; hence the importance of its understanding for the treatment of autoimmune diseases. Animal models have demonstrated that blockage of the IL-17 receptor (IL-17R) may prevent these pathologies. For instance, there is evidence that IL...

Trends in the prevalence and incidence of psoriasis and psoriatic arthritis in Ontario, Canada: A population-based study.

To estimate the prevalence and incidence of psoriasis and psoriatic arthritis (PsA) over time in Ontario, Canada.

Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies.

Wide-ranging prevalence estimates of psoriatic arthritis (PsA) in patients with psoriasis have been reported.

Higher Incidence Rates of Comorbidities in Patients with Psoriatic Arthritis Compared with the General Population Using U.S. Administrative Claims Data.

Psoriatic arthritis (PsA) is associated with multiple comorbid conditions, including cardiovascular (CV) comorbidities that impose a considerable burden on patients. Effective management of PsA requires an understanding of comorbidity profiles.


Advertisement
Quick Search
Advertisement
Advertisement